Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | REN | P00797 | 7/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13490820 | 0.93 | USP30 (0.41) | CYP3A4USP30GPR119RENJAK2 | |
| SCHEMBL8263839 | 0.93 | GPR119 (0.39) | CYP3A4USP30GPR119RENJAK2 | |
| SCHEMBL8265119 | 0.92 | CYP3A4 (0.42) | CYP3A4GPR119REN | |
| SCHEMBL8263850 | 0.92 | CYP3A4 (0.41) | CYP3A4GPR119REN | |
| SCHEMBL8262730 | 0.92 | P2RX3 (0.40) | USP30GPR119RENJAK2JAK1 | |
| SCHEMBL8264237 | 0.92 | REN (0.45) | CYP3A4USP30REN | |
| SCHEMBL8263338 | 0.90 | REN (0.41) | CYP3A4USP30GPR119RENJAK2 | |
| SCHEMBL8264190 | 0.90 | GPR119 (0.42) | CYP3A4USP30GPR119RENJAK2 | |
| SCHEMBL13490822 | 0.89 | USP30 (0.40) | USP30GPR119RENJAK2JAK1 | |
| SCHEMBL13490819 | 0.89 | USP30 (0.41) | USP30GPR119JAK2JAK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| WO-2006074924-A1 | 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | CYP3A4 70/4885USP30 4527/4885GPR119 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.